BI 54903
Drug timelines are a Plus or Pro feature.
5 regulatory and trial events tracked for BI 54903, covering 2011-11-23 to 2022-06-23. Get the full timeline:
Most recent: Clinical Trial Update: Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS). [Phase 2]